Could laser-facilitated epicutaneous vaccination for SARS-CoV-2 be an alternative to intramuscular injection?

By | February 23, 2021
Scientists at the University of Salzburg and Pantec Biosolutions AG have developed a laser-facilitated epicutaneous immunization against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. The model has induced angiotensin-converting enzyme 2 (ACE2) blocking antibodies in mice.